MarketCap
Facebook
X
TelegramAnnual report 2025
added 04-18-2026
Novartis AG Cash and Cash Equivalents 2011-2026 | NVS
Annual Cash and Cash Equivalents Novartis AG
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 11.4 B | 11.5 B | 13.4 B | 7.52 B | 12.4 B | 9.66 B | 11.1 B | 13.3 B | 8.86 B | 7.01 B | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 13.4 B | 7.01 B | 10.6 B |
Quarterly Cash and Cash Equivalents Novartis AG
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 3.62 B | 13.9 B | 12.4 B | - | 5.12 B | 3.8 B | 9.66 B | - | 5.92 B | 4.53 B | 11.1 B | - | 9.99 B | 6.81 B | 13.3 B | - | 12.4 B | 5.81 B | 8.86 B | - | 7.86 B | 7.57 B | 7.01 B | - | - | - | 4.67 B | - | - | - | 13 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 13.9 B | 3.62 B | 8.37 B |
Cash and Cash Equivalents of other stocks in the Biotechnology industry
| Issuer | Cash and Cash Equivalents | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Applied Genetic Technologies Corporation
AGTC
|
46.4 M | - | - | $ 26.5 M |  USA |
 |
MorphoSys AG
MOR
|
158 M | - | 2.43 % | $ 254 M |  Germany |
 |
Allakos
ALLK
|
66.4 M | - | - | $ 28.6 M | USA |
 |
Advaxis
ADXS
|
4.88 M | - | -9.65 % | $ 45.9 M | USA |
 |
Akouos
AKUS
|
122 M | - | 0.23 % | $ 488 M | USA |
 |
AlloVir
ALVR
|
98.1 M | - | 4.14 % | $ 49.1 M | USA |
 |
Compugen Ltd.
CGEN
|
7.8 M | $ 2.59 | -5.31 % | $ 242 M |  Israel |
 |
I-Mab
IMAB
|
4.76 B | - | - | $ 866 M |  China |
 |
Aeglea BioTherapeutics
AGLE
|
85.7 M | - | - | $ 1.01 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
4.09 M | - | -11.43 % | $ 502 K | USA |
 |
Midatech Pharma plc
MTP
|
8.53 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Aptorum Group Limited
APM
|
3.5 M | $ 0.88 | 0.34 % | $ 6.47 M | China |
 |
Biophytis SA
BPTS
|
5.57 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
81.8 M | - | 2.54 % | $ 160 B | France |
 |
ACADIA Pharmaceuticals
ACAD
|
320 M | $ 22.44 | -1.01 % | $ 3.72 B | USA |
 |
Evogene Ltd.
EVGN
|
13 M | $ 0.79 | -0.65 % | $ 27.9 M | Israel |
 |
Applied Molecular Transport
AMTI
|
61.1 M | - | - | $ 10.1 M | USA |
 |
Fennec Pharmaceuticals
FENC
|
36.8 M | $ 6.23 | -7.01 % | $ 178 M | USA |
 |
AIkido Pharma
AIKI
|
34 M | - | 1.93 % | $ 17.4 M | USA |
 |
Applied Therapeutics
APLT
|
49.9 M | - | - | $ 8.42 M | USA |
 |
Galapagos NV
GLPG
|
87.9 M | $ 27.99 | -1.51 % | $ 2.69 B |  Belgium |
 |
Aptinyx
APTX
|
56.2 M | - | -39.0 % | $ 4.57 M | USA |
 |
Avenue Therapeutics
ATXI
|
2.86 M | - | -52.27 % | $ 4.45 M | USA |
 |
ImmuCell Corporation
ICCC
|
3.81 M | $ 8.43 | 0.96 % | $ 76.1 M | USA |
 |
Aeterna Zentaris
AEZS
|
7.31 M | - | 5.93 % | $ 314 M |  Canada |
 |
Ayala Pharmaceuticals
AYLA
|
2.41 M | - | - | $ 7.46 M | Israel |
 |
AgeX Therapeutics
AGE
|
3.06 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aravive
ARAV
|
53.7 M | - | -13.39 % | $ 1.45 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
4.88 M | - | 17.91 % | $ 11.1 M | USA |
 |
Atreca
BCEL
|
30.8 M | - | -11.76 % | $ 5.79 M | USA |
 |
BioNTech SE
BNTX
|
7.68 B | $ 100.41 | -1.62 % | $ 27.2 B | Germany |
 |
Brainstorm Cell Therapeutics
BCLI
|
29 K | - | -2.5 % | $ 5.88 M | USA |
 |
BioDelivery Sciences International
BDSI
|
112 M | - | -4.8 % | $ 255 M | USA |
 |
Innoviva
INVA
|
551 M | $ 23.19 | -2.11 % | $ 1.56 B | USA |
 |
Innate Pharma S.A.
IPHA
|
28.1 M | $ 1.45 | 3.57 % | $ 235 M | France |
 |
Inventiva S.A.
IVA
|
96.6 M | $ 4.95 | -1.3 % | $ 138 M | France |
 |
Jaguar Health
JAGX
|
968 K | $ 0.23 | -5.44 % | $ 536 K | USA |
 |
Aquestive Therapeutics
AQST
|
121 M | $ 4.07 | -0.61 % | $ 435 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
42.9 M | $ 22.53 | -3.28 % | $ 2.87 B | USA |
 |
KalVista Pharmaceuticals
KALV
|
229 M | $ 26.7 | 38.77 % | $ 1.44 B | Britain |
 |
Autolus Therapeutics plc
AUTL
|
104 M | $ 1.43 | -3.72 % | $ 381 M | Britain |
 |
Kamada Ltd.
KMDA
|
75.5 M | $ 8.16 | 0.12 % | $ 260 M | Israel |
 |
Aptose Biosciences
APTO
|
935 K | - | -45.71 % | $ 1.2 M | Canada |
 |
AstraZeneca PLC
AZN
|
5.71 B | - | - | $ 96.9 B | Britain |
 |
AVROBIO
AVRO
|
98 M | - | 1083.1 % | $ 745 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
8.27 M | $ 2.95 | 1.2 % | $ 4.86 M | Israel |
 |
BeiGene, Ltd.
BGNE
|
4.55 B | - | 0.49 % | $ 251 B |  Cayman-islands |